Home > Insider Trading > Filing (0001209191-16-153507)

Filing Details

Accession Number:: 0001209191-16-153507
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-12-05 19:03:32
Reporting Period:: 2016-12-01

Filing Date:: 2016-12-05
Accepted Time:: 2016-12-05 19:03:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510580	Kite Pharma Inc.	KITE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610823	Jeffrey Wiezorek	C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404	Svp Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-12-01	1,500	$6.89	17,311	No	4	M	Direct
Common Stock	Disposition	2016-12-01	1,293	$50.68	16,018	No	4	S	Direct
Comon Stock	Disposition	2016-12-01	207	$51.23	15,811	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2016-11-10	1,500	$0.00	1,500	$6.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
89,000		2024-06-05	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.02 to $51.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
On June 6, 2014, the Reporting Person was granted options to purchase an aggregate of 200,000 shares of the Issuer's common stock. An option to purchase 25,000 of such shares was granted subject to the Issuer's satisfaction of certain performance criteria, which were met on November 30, 2015, and upon which the option vested in full. The remaining 175,000 shares vest as follows: 25% on May 5, 2015, with the remaining shares vesting in 36 equal monthly installments thereafter. The grants have been reported separately on prior Form 4's, but because they have identical material terms, the Reporting Person elects to aggregate the grants on this report, as well as any future reports.